Actively Recruiting
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Led by Qilu Pharmaceutical Co., Ltd. · Updated on 2026-02-27
228
Participants Needed
1
Research Sites
212 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to compare the safety and efficacy of QLS32015 with Pd/Sd for the treatment of relapsed or refractory multiple myeloma.
CONDITIONS
Official Title
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older, any gender
- Willingness and ability to comply with study schedule and protocols
- Documented diagnosis of multiple myeloma by International Myeloma Working Group criteria with measurable disease defined by serum M-protein 1 g/dL, or urine M-protein 200 mg/24 hours, or abnormal serum free light chain assay with involved FLC 10 mg/dL and abnormal FLC ratio
- Received at least 3 prior lines of therapy including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody
You will not qualify if you...
- Known hypersensitivity to any ingredients of study drugs
- Diagnosis of active plasma cell leukemia or systemic light chain amyloidosis
- Presence of active severe mental illness, medical illness, or symptoms affecting treatment, compliance, or consent ability as judged by investigator
- Disease refractory to pomalidomide and selinexor
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Clinical Research Center for Blood Diseases
Tianjin, Tianjin Municipality, China
Actively Recruiting
Research Team
G
Gang An, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here